Contributions of Basal and Postprandial Hyperglycemia Over a Wide Range of A1C Levels Before and After Treatment Intensification in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine the relative contributions of basal hyperglycemia (BHG) versus postprandial hyperglycemia (PPHG) before and after treatment intensification in patients with glycated hemoglobin A1c (A1C) >7.0% while on prior oral therapy. RESEARCH DESIGN AND METHODS: Self-measured, plasma-referenced glucose profiles and A1C values were evaluated from participants in six studies comparing systematically titrated insulin glargine with an alternative regimen (adding basal, premixed, or prandial insulin, or increasing oral agents). Hyperglycemic exposure (>100 mg/dL [5.6 mmol/L]) as a result of BHG versus PPHG was calculated. RESULTS: On prior oral therapy, 1,699 participants (mean age 59 years, diabetes duration 9 years) had mean fasting plasma glucose (FPG) of 194 mg/dL (10.8 mmol/L), and mean A1C was 8.7%. BHG contributed an average of 76–80% to hyperglycemia over the observed range of baseline A1C levels. Adding basal insulin for 24 or 28 weeks lowered mean FPG to 117 mg/dL (6.5 mmol/L), A1C to 7.0%, and BHG contribution to 32–41%. Alternative regimens reduced FPG to 146 mg/dL (8.1 mmol/L), A1C to 7.1%, and the contribution of BHG to 64–71%. BHG contributions for patients with A1C averaging 7.6–7.7% were 76% at baseline and 34 and 68% after adding basal insulin or other therapies, respectively. CONCLUSIONS: When A1C is >7.0% despite oral therapy, BHG routinely dominates exposure. Intensified therapy reduces A1C and changes this relationship, but BHG amenable to further intervention still accounts for one-third of total hyperglycemia after basal insulin treatment and two-thirds after alternative methods.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When A1C values are higher, the major contribution is the FPG levels, but as the A1C value approaches the target value of ≤7.0%, there is a greater contribution from PPG values (37-39).”
From Targets for Glycemic Control (2018) · cites this paper as [39]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Follow-up report on the diagnosis of diabetes mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3160 · Cited by 3,784
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s5 · Cited by 2,689
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461 · cited 3×
“89) AUCB (mg z h z dL (21)) Baseline 2,155 (1,176) 2,271 (1,183) 1,821 (1,091) 2,598 (1,220) 2,449 (1,256)”
BackgroundInfluentialMonnier, L., Colette, C., Dunseath, G. J., & Owens, D. R. (2007) · Diabetes Care · doi:10.2337/dc06-1612 · Cited by 490
Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study
Yki-Järvinen, H., Kauppinen-Mäkelin, R., Tiikkainen, M., Vähätalo, M., Virtamo, H., Nikkilä, K., Tulokas, T., Hulme, S., Hardy, K., McNulty, S., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0132-0 · Cited by 434
Janka, H. U., Plewe, G., Riddle, M. C., Kliebe-Frisch, C., Schweitzer, M. A., & Yki-Järvinen, H. (2005) · Diabetes Care · doi:10.2337/diacare.28.2.254 · Cited by 414
Self-citation
Cited by
Items 201–225 of 225
InSUlIn InItIatIOn In type 2 DIabeteS
Wu, T., & Specialist, S. (2015)
Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an alliance
Ruyatkina, L. A., & Sorokin, M. (2016) · Diabetes Mellitus · doi:10.14341/7875
Fleming, G. A., & Harvey, B. E. (2019) · Springer eBooks · doi:10.1007/978-3-030-11748-1_19 · Cited by 1
Kreß, S., Borck, A., Zisman, A., Bramlage, P., & Siegmund, T. (2019) · Diabetologie und Stoffwechsel · doi:10.1055/a-0958-2034
Handelsman, Y., Muskiet, M. H. A., & Meneilly, G. S. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01185-0
Kreß, S., Borck, A., Zisman, A., Bramlage, P., & Siegmund, T. (2020) · Diabetes aktuell · doi:10.1055/a-1145-4047
Хусанходжаева, М. З., Rakhimova, G., & Mullabaeva, G. (2020)
Kreß, S., Borck, A., Zisman, A., Bramlage, P., & Siegmund, T. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s267882
Cheng, Y., Li, Q., Yi, F., Chen, L.-P., Yuan, L., Yan, J.-Q., Gao, L., Qi, Y. X., Sun, Q., Ding, F., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-535126/v1
Faster Aspart: a fast-acting insulin analog for an optimal glycemic control
Irace, C. (2021) · The Journal of AMD · doi:10.36171/jamd21.24.3.5
Li, Q., Zhang, Q., Wang, R., & Hong, T. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01182-z
Moller, J., Kristensen, N. R., Klim, S., Karlsson, M., Ingwersen, S., & Kjellsson, M. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12080
INTENSIVE HYPOGLYCEMIC THERAPY AS A TRIGGER FOR ELECTRICAL MYOCARDIAL INSTABILITY
Mirzarakhimova Zulfiya Khusankhodzhaevna, R. G. N. (2021) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.5585470
Gourdy, P., Bahloul, A., Safsaf, S., Roux, B., Pape, G. L., & Krempf, M. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.06.005
Moon, S. J., Hong, J. H., Kim, S. S., Kim, K., Lim, S. K., Jin, H. Y., Hwang, Y., Lee, S., Lee, K., Kang, J. G., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4608008
Quinine: rediscovery of an old glucose-lowering drug. Reply to Henquin J-C [letter]
Anjom-Shoae, J., Horowitz, M., & Feinle‐Bisset, C. (2025) · Diabetologia · doi:10.1007/s00125-025-06415-5
Jun, J. E., Choi, S. H., Moon, M. K., Ko, S., Kim, H. J., Hur, K. Y., Rhee, E., Noh, J. H., & Jeong, I. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16557
Proteins and the crossroads of diet and type 2 diabetes
Anjom-Shoae, J., Wu, T., & Horowitz, M. (2025) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.08.004
Anjom-Shoae, J., Fitzgerald, P. C. E., Rose, B. D., Bitarafan, V., Rehfeld, J. F., Horowitz, M., & Feinle‐Bisset, C. (2025) · Diabetologia · doi:10.1007/s00125-025-06630-0
Sun, Y., Luo, Y., Xie, C., Jones, K. L., Horowitz, M., Rayner, C. K., Ma, J., & Wu, T. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70327
Xiang, X., Zhang, G., Hamaker, B. R., & Miao, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33285-2.00007-0
Postprandial Matters: Identifying Multifactorial Determinants and Rethinking Glucose Monitoring
Wangnoo, S., Das, A. K., Viswanathan, V., Sanyal, D., Chawla, R., Mittal, S., Gangopadhyay, K. K., Dasgupta, A., Iyer, R., Sugumaran, A., et al. (2026) · Journal of Diabetology · doi:10.4103/jod.jod_231_25
Mohammadi, E. S., Gharabagh, L. H., & Hajiesmaello, M. (2026) · PubMed Central · doi:10.22088/cjim.17.2.319
Social Physiology: Human homeostasis is more efficient in social proximity
Masalha, M., Cohen, M. T., Aloni, M., Toledo, E., Stahl, E., Shachar, D., Eliav, O., Fuchs, S., & Atzil, S. (2026) · Science Advances · doi:10.1126/sciadv.aeg4937 · Cited by 1
INTENSIVE HYPOGLYCEMIC THERAPY AS A TRIGGER FOR ELECTRICAL MYOCARDIAL INSTABILITY
Mirzarakhimova, Z. K., Рахимова, Г. Н., & Муллабаева, Г. У. (2021) · European journal of molecular medicine
Metadata
- Authors
- Riddle, M., Umpierrez, G., DiGenio, A., Zhou, R., & Rosenstock, J.
- Affiliations
- Oregon Health & Science University (US)
- Emory University (US)
- Sanofi (United States) (US)
- Medpace (United States) (US)
- Dallas Diabetes and Endocrine Center, Dallas, Texas
- Corresponding author
- Riddle, Matthew
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-11-14
- Volume
- 34
- Issue
- 12
- Pages
- 2508-2514
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3220846
- OpenAlex
- W2103903409
- Cited by
- 219
- References
- 20
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 6 · 2023: 4 · 2022: 7 · 2021: 12 · 2020: 13 · 2019: 22 · 2018: 13 · 2017: 17 · 2016: 18 · 2015: 28 · 2014: 22 · 2013: 29 · 2012: 8
- FWCI
- 16.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Medpace
- MannKind Corporation
- European Foundation for the Study of Diabetes
- Novo Nordisk
- National Institutes of Health (UL1TR000454)
- National Center for Advancing Translational Sciences
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, postprandial hyperglycemia, HbA1c, treatment intensification, insulin glargine, basal insulin, oral antidiabetic drugs, fasting blood glucose, glycemic control
- MeSH terms
- Isophane Insulin, Human, Insulin Glargine, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hyperglycemia, Insulin, Isophane, Male, Middle Aged, Randomized Controlled Trials as Topic, Treatment Outcome, Insulin, Long-Acting, Insulin, Regular, Human
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.